NYSE:LLY - Eli Lilly And Co News Headlines

Sign in or create an account to add this stock to your watchlist.
$116.66 -1.32 (-1.12 %)
(As of 05/23/2019 02:44 PM ET)
Previous Close$117.98
Today's Range$116.55 - $117.94
52-Week Range$81.61 - $132.13
Volume126,739 shs
Average Volume4.29 million shs
Market Capitalization$113.26 billion
P/E Ratio21.01
Dividend Yield2.21%
Beta0.27

Headlines

Eli Lilly And Co (NYSE LLY) News Headlines

Source:
DateHeadline
Eli Lilly And Co (LLY) Given Average Rating of "Buy" by BrokeragesEli Lilly And Co (LLY) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 23 at 2:27 PM
Should We Worry About Eli Lilly and Companys (NYSE:LLY) P/E Ratio?Should We Worry About Eli Lilly and Company's (NYSE:LLY) P/E Ratio?
finance.yahoo.com - May 22 at 7:05 PM
Array BioPharma Gains on Colorectal Cancer Study SuccessArray BioPharma Gains on Colorectal Cancer Study Success
finance.yahoo.com - May 22 at 7:05 PM
Eli Lillys Insulin Lispro Injection available at half the list price of HumalogEli Lilly's Insulin Lispro Injection available at half the list price of Humalog
www.marketwatch.com - May 22 at 8:34 AM
Lilly selling half-price version of popular Humalog insulinLilly selling half-price version of popular Humalog insulin
marketbeat.com - May 22 at 6:48 AM
Lillys Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal LesionsLilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions
finance.yahoo.com - May 21 at 7:13 PM
Why This Biotech Stock Succeeded In Colon Cancer As Others StruggledWhy This Biotech Stock Succeeded In Colon Cancer As Others Struggled
finance.yahoo.com - May 21 at 7:13 PM
Why Eli Lilly (LLY) is a Top Dividend Stock for Your PortfolioWhy Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
www.nasdaq.com - May 20 at 11:41 PM
Top Money Manager Recommends Eli Lilly On Recent Market DipTop Money Manager Recommends Eli Lilly On Recent Market Dip
www.forbes.com - May 19 at 4:15 PM
Better Buy: Eli Lilly vs. PfizerBetter Buy: Eli Lilly vs. Pfizer
finance.yahoo.com - May 19 at 9:07 AM
Data Presentations at ASCO 2019 Highlight Lillys Targeted Approach to Developing Treatments for Patients Living with CancerData Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer
finance.yahoo.com - May 15 at 8:23 PM
Eli Lilly Announces FDA Approval Of CYRAMZA For New IndicationEli Lilly Announces FDA Approval Of CYRAMZA For New Indication
www.finanznachrichten.de - May 13 at 8:35 AM
Lillys CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular CarcinomaLilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
finance.yahoo.com - May 13 at 8:35 AM
Two Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary EndpointsTwo Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary Endpoints
www.prnewswire.com - May 7 at 8:14 PM
Insider Selling: Eli Lilly And Co (LLY) SVP Sells 7,577 Shares of StockInsider Selling: Eli Lilly And Co (LLY) SVP Sells 7,577 Shares of Stock
www.americanbankingnews.com - May 7 at 2:33 PM
Eli Lilly And Co Plans Quarterly Dividend of $0.65 (LLY)Eli Lilly And Co Plans Quarterly Dividend of $0.65 (LLY)
www.americanbankingnews.com - May 6 at 4:30 PM
Lilly Declares Second-Quarter 2019 DividendLilly Declares Second-Quarter 2019 Dividend
www.prnewswire.com - May 6 at 2:37 PM
Edited Transcript of LLY earnings conference call or presentation 30-Apr-19 1:00pm GMTEdited Transcript of LLY earnings conference call or presentation 30-Apr-19 1:00pm GMT
finance.yahoo.com - May 6 at 8:37 AM
AAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine SubgroupsAAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups
finance.yahoo.com - May 6 at 8:37 AM
Global Cyclin Dependent Kinase 6 Market 2018- Beta Pharma Inc, Eli Lilly And Company, FLX Bio IncGlobal Cyclin Dependent Kinase 6 Market 2018- Beta Pharma Inc, Eli Lilly And Company, FLX Bio Inc
www.marketwatch.com - May 4 at 8:43 AM
Flippin Bruce & Porter Inc Buys Norfolk Southern Corp, Sells Eli Lilly and CoFlippin Bruce & Porter Inc Buys Norfolk Southern Corp, Sells Eli Lilly and Co
finance.yahoo.com - May 3 at 7:03 PM
Migraine drugs cause pain for investorsMigraine drugs cause pain for investors
finance.yahoo.com - May 3 at 7:03 PM
FY2019 Earnings Forecast for Eli Lilly And Co Issued By Cantor Fitzgerald (LLY)FY2019 Earnings Forecast for Eli Lilly And Co Issued By Cantor Fitzgerald (LLY)
www.americanbankingnews.com - May 3 at 9:42 AM
Global Erectile Dysfunction (ED) Drugs Market to 2023 with Bayer, Eli Lilly and Co, Pfizer, Teva Pharma, & Vivus DominatingGlobal Erectile Dysfunction (ED) Drugs Market to 2023 with Bayer, Eli Lilly and Co, Pfizer, Teva Pharma, & Vivus Dominating
www.prnewswire.com - May 2 at 8:42 AM
Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders PortfolioLilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio
finance.yahoo.com - May 2 at 8:42 AM
Eli Lilly And Co (LLY) Given New $133.00 Price Target at BMO Capital MarketsEli Lilly And Co (LLY) Given New $133.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - May 1 at 11:13 AM
Eli Lilly misses on revenue in face of pricing pressures and growing generic competitionEli Lilly misses on revenue in face of pricing pressures and growing generic competition
finance.yahoo.com - May 1 at 8:31 AM
Eli Lilly And Co (LLY) Earning Somewhat Favorable Media Coverage, Study ShowsEli Lilly And Co (LLY) Earning Somewhat Favorable Media Coverage, Study Shows
www.americanbankingnews.com - May 1 at 5:52 AM
Eli Lilly and Company (LLY) Q1 2019 Earnings Call TranscriptEli Lilly and Company (LLY) Q1 2019 Earnings Call Transcript
www.fool.com - May 1 at 12:10 AM
Eli Lilly And Co (LLY) Rating Reiterated by Cantor FitzgeraldEli Lilly And Co (LLY) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - April 30 at 9:40 PM
UPDATE 2-Eli Lilly misses estimates for diabetes drug Trulicity, cuts revenue forecastUPDATE 2-Eli Lilly misses estimates for diabetes drug Trulicity, cuts revenue forecast
www.cnbc.com - April 30 at 6:40 PM
Whats Behind Eli Lillys Mixed Q1 ResultsWhat's Behind Eli Lilly's Mixed Q1 Results
www.fool.com - April 30 at 6:40 PM
Eli Lilly slashes guidance in face of pricing pressures and growing generic competitionEli Lilly slashes guidance in face of pricing pressures and growing generic competition
www.marketwatch.com - April 30 at 6:40 PM
US stock Indicators waver on mixed earnings; Alphabet downUS stock Indicators waver on mixed earnings; Alphabet down
www.americanbankingnews.com - April 30 at 5:04 PM
US stock indexes waver on mixed earnings; Alphabet downUS stock indexes waver on mixed earnings; Alphabet down
marketbeat.com - April 30 at 4:16 PM
US stock Indicators Slide on earnings; Alphabet tumblesUS stock Indicators Slide on earnings; Alphabet tumbles
www.americanbankingnews.com - April 30 at 3:04 PM
US stock indexes slip on mixed earnings; Alphabet tumblesUS stock indexes slip on mixed earnings; Alphabet tumbles
marketbeat.com - April 30 at 2:25 PM
Earnings Results: Eli Lilly slashes guidance in face of pricing pressures and growing generic competitionEarnings Results: Eli Lilly slashes guidance in face of pricing pressures and growing generic competition
www.marketwatch.com - April 30 at 11:37 AM
Eli Lilly And Co (LLY) Issues  Earnings Results, Beats Estimates By $0.01 EPSEli Lilly And Co (LLY) Issues Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - April 30 at 11:05 AM
Eli Lilly And Co (LLY) Issues FY19 Earnings GuidanceEli Lilly And Co (LLY) Issues FY19 Earnings Guidance
www.americanbankingnews.com - April 30 at 10:22 AM
UPDATE 1-Eli Lilly cuts revenue forecast, shares fallUPDATE 1-Eli Lilly cuts revenue forecast, shares fall
www.cnbc.com - April 30 at 8:32 AM
Eli Lillys stock sinks after earnings beat but revenue comes up short, hurt by Trulicity and Alimta missesEli Lilly's stock sinks after earnings beat but revenue comes up short, hurt by Trulicity and Alimta misses
www.marketwatch.com - April 30 at 8:32 AM
Eli Lilly Reports Better-Than-Expected Earnings but Shares DeclineEli Lilly Reports Better-Than-Expected Earnings but Shares Decline
www.thestreet.com - April 30 at 8:32 AM
Eli Lilly And Co. Q1 adjusted earnings Beat EstimatesEli Lilly And Co. Q1 adjusted earnings Beat Estimates
www.finanznachrichten.de - April 30 at 8:32 AM
Eli Lilly quarterly profit more than triples on Elanco gainEli Lilly quarterly profit more than triples on Elanco gain
www.cnbc.com - April 30 at 8:32 AM
Eli Lilly misses estimates for diabetes drug Trulicity, cuts revenue forecastEli Lilly misses estimates for diabetes drug Trulicity, cuts revenue forecast
finance.yahoo.com - April 30 at 8:32 AM
Eli Lilly And Co (LLY) Updates FY 2019 Earnings GuidanceEli Lilly And Co (LLY) Updates FY 2019 Earnings Guidance
www.americanbankingnews.com - April 30 at 7:46 AM
Earnings Watch: Insulin-maker Eli Lilly is scheduled to report earnings Tuesday. Here’s what to expect Earnings Watch: Insulin-maker Eli Lilly is scheduled to report earnings Tuesday. Here’s what to expect
www.marketwatch.com - April 29 at 4:47 PM
Tomorrow Is Earnings Day for Big Pharma. Here’s What to Watch.Tomorrow Is Earnings Day for Big Pharma. Here’s What to Watch.
finance.yahoo.com - April 29 at 8:30 AM
Week In Review: Eddingpharm To Pay $375 Million For 2 Lilly Antibiotics And A Suzhou Manufacturing FacilityWeek In Review: Eddingpharm To Pay $375 Million For 2 Lilly Antibiotics And A Suzhou Manufacturing Facility
seekingalpha.com - April 28 at 5:51 PM
This page was last updated on 5/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel